Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.80, $0.43 better than the analyst estimate of $1.37. Revenue for the quarter came in at $72.5 million versus the consensus estimate of $65.32 million.

GUIDANCE:

Ligand Pharma sees FY2022 revenue of $147-172 million, versus the consensus of $189 million.

• Ligand is providing 2022 revenue guidance for the combined business as well as some information about revenue that is estimated to be attributable to the OmniAb business anticipating the spin-off later this year. Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million. These revenue components result in total revenue of $147 million to $172 million for the combined Ligand business. Ligand estimates two-thirds of the contract revenue guidance to be attributable to OmniAb and a couple million of the royalty revenue will be attributable to OmniAb. Following the completion of the separation process, Ligand will provide more detailed guidance on expenses and earnings.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.